VolitionRx Gestione

Gestione criteri di controllo 3/4

VolitionRx Il CEO è Cameron Reynolds, nominato in Jan2010, e ha un mandato di 14.83 anni. la retribuzione annua totale è $ 772.93K, composta da 50.6% di stipendio e 49.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.39% delle azioni della società, per un valore di $ 1.04M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 3.3 anni.

Informazioni chiave

Cameron Reynolds

Amministratore delegato

US$772.9k

Compenso totale

Percentuale dello stipendio del CEO	50.6%
Mandato del CEO	14.8yrs
Proprietà del CEO	1.4%
Durata media del management	3.8yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Do Institutions Own VolitionRx Limited (NYSEMKT:VNRX) Shares?

Mar 17

This Insider Has Just Sold Shares In VolitionRx Limited (NYSEMKT:VNRX)

Feb 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Cameron Reynolds rispetto agli utili di VolitionRx?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$32m
Mar 31 2024	n/a	n/a	-US$35m
Dec 31 2023	US$773k	US$391k	-US$35m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$761k	n/a	-US$30m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$982k	n/a	-US$27m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$563k	US$364k	-US$20m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$518k	US$391k	-US$16m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$660k	US$398k	-US$18m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$16m
Dec 31 2017	US$690k	US$294k	-US$15m

Compensazione vs Mercato: La retribuzione totale di Cameron ($USD 772.93K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 652.28K ).

Compensazione vs guadagni: La retribuzione di Cameron è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Cameron Reynolds (53 yo)

14.8yrs

Mandato

US$772,933

Compensazione

Mr. Cameron Reynolds, MBA, founded VolitionRX in 2010 and has been its President, Chief Executive Officer and Director since October 6, 2011. Mr. Reynolds has been Independent Non-Executive Director of Pat...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Cameron Reynolds	Founder	14.8yrs	US$772.93k	1.39% $ 1.0m
Gaetan Michel	Chief Operating Officer	3.8yrs	US$667.81k	0.052% $ 39.1k
Salvatore Butera	Chief Executive Officer of Volition Veterinary Diagnostics Development LLC	3.5yrs	US$619.79k	0.27% $ 202.1k
Terig Hughes	CFO & Treasurer	3.8yrs	US$513.23k	0.053% $ 39.7k
Jacob Micallef	Chief Scientific Officer	9.8yrs	US$657.89k	0.30% $ 226.3k
Nicholas Plummer	Group General Counsel	3yrs	Nessun dato	0.092% $ 69.0k
Louise Batchelor Day	Group Chief Marketing & Communications Officer	8.6yrs	Nessun dato	0.075% $ 55.7k
Gael Forterre	Chief Commercial Officer	3.8yrs	Nessun dato	0.11% $ 78.5k
Sharon Ballesteros	U.S. Head of Quality & Development Process	2.6yrs	Nessun dato	Nessun dato
Andrew Retter	Chief Medical Officer	less than a year	Nessun dato	Nessun dato
Rodney Rootsaert	Corporate Secretary	13.1yrs	US$262.72k	0.075% $ 55.7k
Jasmine Kway	Chief Executive Officer of Singapore Volition	6.4yrs	Nessun dato	0.059% $ 43.9k

3.8yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di VNRX è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Cameron Reynolds	Founder	13.1yrs	US$772.93k	1.39% $ 1.0m
Timothy Still	Chairman	no data	Nessun dato	Nessun dato
Guy Innes	Lead Independent Director	13.1yrs	US$61.94k	2.59% $ 1.9m
Mickie Henshall	Independent Director	2.3yrs	US$2.22k	0.020% $ 15.2k
Ethel Rubin	Independent Director	less than a year	Nessun dato	Nessun dato
Mark Eccleston	Member of Scientific Advisory Board	less than a year	US$252.77k	Nessun dato
Phillip Barnes	Independent Non-Executive Director	5.1yrs	US$61.94k	0.016% $ 11.9k
Alan Colman	Member of Scientific Advisory Board & Independent Non Executive Director	13.1yrs	US$86.00k	0.18% $ 136.3k
Axel Imhof	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Kim Nguyen	Independent Director	3.7yrs	US$61.94k	0.063% $ 46.8k
Timothy Fan	Member of Scientific Advisory Board	2.8yrs	Nessun dato	Nessun dato
Alexander Hoffmann	Member of Scientific Advisory Board	1.8yrs	Nessun dato	Nessun dato

3.3yrs

Durata media

55.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VNRX sono considerati esperti (durata media dell'incarico 3.3 anni).

VolitionRx Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Volitionrx Limited Appoints Timothy Still as Chairman, Effective November 6, 2024

High number of new directors

VolitionRx Limited Appoints Dr. Ethel Rubin as an Independent Director and Member of the Audit Committee and the Compensation Committee

VolitionRx Limited, Annual General Meeting, Jul 02, 2024

Volitionrx Limited Appoints Andrew Retter as Chief Medical Officer, Effective April 1, 2024

High number of new directors

Recent updates

Forecast to breakeven in 2026

Third quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Volitionrx Limited Appoints Timothy Still as Chairman, Effective November 6, 2024

High number of new directors

VolitionRx Limited Appoints Dr. Ethel Rubin as an Independent Director and Member of the Audit Committee and the Compensation Committee

Forecast to breakeven in 2026

Price target decreased by 11% to US$3.09

Consensus revenue estimates decrease by 11%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.9% to US$3.47

Consensus revenue estimates decrease by 16%, EPS upgraded

New minor risk - Profitability

Consensus revenue estimates increase by 23%, EPS downgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

VolitionRx Limited, Annual General Meeting, Jul 02, 2024

VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech

Consensus revenue estimates fall by 43%

New minor risk - Profitability

Forecast to breakeven in 2026

Full year 2023 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited announced that it has received $0.1 million in funding

Volitionrx Limited Appoints Andrew Retter as Chief Medical Officer, Effective April 1, 2024

High number of new directors

VolitionRx Limited announced that it has received €2.5 million in funding

Consensus revenue estimates decrease by 22%, EPS upgraded

New major risk - Negative shareholders equity

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 7.2% to US$3.66

VolitionRx Limited Presents Breakthrough Liquid Biopsy Blood Test Method for Early-Stage Cancer

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

Consensus revenue estimates decrease by 45%

Forecast to breakeven in 2025

Price target decreased by 11% to US$4.94

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $7.525 million.

Price target decreased by 9.7% to US$5.21

Chief Scientific Officer recently bought US$72k worth of stock

Volitionrx Limited Announces Resignation of Dr. Jason Terrell as Chief Medical Officer

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Volition Announces the Launch of the Nu.Q(R) Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Consensus revenue estimates fall by 19%

VolitionRx Limited Appoints Mickie Henshall as Independent Director

Price target decreased to US$6.71

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 94%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited Launches its Nu.Q® Vet Cancer Test in Asia

VolitionRx Limited Appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

Consensus revenue estimates increase by 253%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2020)

Consensus revenue estimates fall to US$530.0k

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.12 loss in 2Q 2020)

VolitionRx Limited Demonstrates Promising Results in Covid-19 Risk Stratification and Disease Monitoring

VolitionRx Limited(NYSEAM:VNRX) dropped from Russell 3000E Value Index

Consensus forecasts updated

Lead Independent Director recently bought US$503k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2020)

Non-Executive Director has left the company

Consensus revenue estimates fall to US$903.7k

Full year 2020 earnings released: US$0.45 loss per share (vs US$0.41 loss in FY 2019)